Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results

m its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the Food and Drug Administration and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release. PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statement of Operations(unaudited)Quarter Ended June 30, Year Ended June 30,2011201020112010REVENUESLicense and contract

497,540$ 14,180,727Grants

131,149-977,917-Total revenues

155,840674,9571,475,45714,180,727OPERATING EXPENSES:Research and development

3,217,3853,554,52110,377,01912,293,910General and administrative

1,525,0261,374,3204,751,8244,901,203Total operating expenses

4,742,4114,928,84115,128,84317,195,113Loss from operations

(4,586,571)(4,253,884)(13,653,386)(3,014,386)OTHER INCOME (EXPENSE):Investment income

26,91621,36599,258141,635Interest expense

(4,999)(3,862)(10,606)(13,165)Decrease/(increase) in fair value of warrants

1,255,425-(2,266)-Gain on sale of securities

--119,346-Gain/(loss) on disposition of supplies and equipment

--(5,666)95,000Total other income, net

1,277,34217,503200,066223,470Loss before income taxes


SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
(Date:10/8/2015)... ... 08, 2015 , ... Cystic fibrosis (CF) is a genetic ... and results in dysfunction of the lungs and the gastrointestinal (GI) tract. In ... is very difficult to clear, blocks the airways and the glands, and creates ...
(Date:10/7/2015)... ... 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal ... Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is one of the ... He is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute ...
(Date:10/7/2015)... 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV ) ... the development and commercialization of targeted antiviral therapies, today ... 5,000,000 shares of its common stock and warrants to ... stock at a fixed combined price to the public ... will be issued separately.  The warrants will be exercisable ...
(Date:10/7/2015)... Pa. , Oct. 7, 2015   VWR ... independent provider of laboratory products, services and solutions, ... Inc. (PTI), a specialty solvent company that performs ... This acquisition will enhance VWR,s growing laboratory and ... laboratory and biopharmaceutical manufacturing customers. Manuel ...
Breaking Biology Technology:
... Integra Merger, IRVINE, California, October 24 IsoTis, ... announced that,it has adjourned the special meeting of stockholders ... IsoTis by Integra LifeSciences Holdings,Corporation (NASDAQ: IART ) ... as of August 6, 2007. The special meeting ...
... ALTO, Calif., Oct. 24 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... quarter 2007 financial results on Tuesday, November 6, 2007,following ... host an investor conference call and live audio webcast ... 6, 2007, at 5:00 p.m.,Eastern Time/2:00 p.m. Pacific Time. ...
... 24 /PRNewswire-FirstCall/ - Atrium Innovations Inc. (TSX:,ATB) will ... 10 a.m. Eastern,time on November 8, 2007. The ... third quarter results issued earlier the previous day.,Participants ... numbers:,416-644-3418, 514-807-8791 or 800-591-7539 or via the Company,s ...
Cached Biology Technology:
(Date:9/30/2015)... Calif. , Sept. 30, 2015  With nearly ... the number of new SCIs estimated to reach 12,500 ... Southern California Resource Services for Independent Living ... ILCs in California opening doors ... range of programs and services, notably assistive technology services ...
(Date:9/29/2015)... SUNNYVALE, Calif. , Sept. 29, 2015 ... technology improves employee productivity while also saving energy ... features such as Low Power Active Mode and embedded ... workplace transformation Fujitsu today shows that ... of new and refreshed models to its enterprise desktop ...
(Date:9/28/2015)... Sept. 28, 2015  The monitoring of vital ... body temperature, is an essential component of patient ... of deterioration in a patient,s condition. However, in ... are typically taken during routine observation rounds only ... patient deteriorates between these observation rounds, the warning ...
Breaking Biology News(10 mins):
... it will expand urea deep placement (UDP)a technology that doubles ... (ha) of rice land, reaching about 1.6 million farm families, ... is the insertion of large urea briquettes into the rice ... who use UDP can increase yields by 25% while using ...
... humile, is one of the most successful invasive species in ... to its native range in South America. A new study ... findings, from researchers at the University of Illinois and the ... the Proceedings of the National Academy of Sciences. The ...
... Richard D. Smith, Battelle Fellow at the U.S. Department ... of 50 outstanding leaders in the 2007 Scientific American 50. ... key contributors in science and technology. Smith shared the ... a colleague from UCLAs David Geffen School of Medicine, Desmond ...
Cached Biology News:
... vectors are designed for enhanced translation of cloned ... rabbit reticulocyte lysate. The maps for pCITE-2b(+) and ... following exceptions: pCITE-2b(+) is a 3793 bp plasmid; ... and Xcm I sites. Subtract 7 bp from ...
Biology Products: